Search Results
Your search for ,ouT matches 5632 pages
Showing 1251 - 1300Achieving Equity in Cancer Care for Adolescents and Young Adults With Cancer
Although cancer in adolescents and young adults (AYAs), defined by the National Cancer Institute as those between the ages of 15 and 39, is relatively rare—in 2020 nearly 90,000 AYAs were diagnosed with cancer and about 9,300 died of the disease1—and 5-year relative survival rates are high, between ...
Expert Point of View: Pilar Garrido, MD, PhD
Invited discussant of CheckMate 743, Pilar Garrido, MD, PhD, pointed out there has been little progress in treating patients with malignant pleural mesothelioma over the past 15 years, and there are limited therapeutic options. Dr. Garrido is Associate Professor of Medical Oncology at Universidad...
Choosing Wisely, Researchers Look at Access to Essential Cancer Drugs on a Global Scale
According to the International Agency for Research on Cancer (IARC), an estimated 19.3 million new cancer cases occurred worldwide in 2020, resulting in almost 10 million deaths. The IARC projects a 50% rise in global cancer incidence and mortality by 2040. To help control this looming crisis,...
Novel Therapies Under Study in Acute Myeloid Leukemia
Newly identified genetic abnormalities in acute myeloid leukemia (AML), as well as therapies that can target some of those abnormalities, are now available as the landscape for treatment continues to evolve. During the 2021 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic...
Friends of Cancer Research Releases White Paper on Optimizing Dosing in Oncology Drug Development
During its virtual Annual Meeting 2021 held on November 9 and 10, Friends of Cancer Research (Friends) urged all stakeholders in the cancer community to work together to optimize dosing in oncology drug development to maximize benefit for patients and reduce treatment toxicity, and to abandon the...
Can SBRT to Selected Sites of Limited Progression or Oligoprogression Extend Progression-Free Survival in Advanced Lung Cancer but Not Breast Cancer?
Stereotactic body radiation therapy (SBRT) lengthens progression-free survival for patients with advanced lung cancer who have oligoprogression (ie, tumors that have not been fully responsive to systemic chemotherapy or immunotherapy), according to an interim analysis of the CURB oligoprogression...
From Cancer Survivor to Citizen Astronaut
When I was diagnosed with osteosarcoma of my left femur nearly 20 years ago, I remember telling my parents that I didn’t want to die. The diagnosis was terrifying because all the people I knew who had cancer had passed away, and I thought this cancer would kill me, too. That evening, my dad went...
Novel Therapies Under Study in Acute Myeloid Leukemia
Newly identified genetic abnormalities in AML have led to novel therapies that can target some of them, as the landscape for treatment continues to evolve. During the 2021 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic Malignancies, Alice S. Mims MD, presented updates in...
Exercise Program May Help to Reduce Upper Limb Disability After Breast Cancer Surgery
Arm and shoulder disability and pain that some women who have had breast cancer surgery experience as a side effect of their procedure may be reduced by following a physiotherapy-led exercise program, according to a new study published by Bruce et al in The BMJ. The report showed an improvement in...
Newer Agents on the Horizon for Refractory or Relapsed DLBCL
Although treating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) remains challenging, some newer therapies on the horizon offer promise, including bispecific antibodies, anti-CD47 antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T-cell therapy,...
Immunotherapy Followed by Targeted Therapy Yields Greater Overall Survival in Patients With BRAF V600–Mutated Advanced Melanoma
Patients with BRAF V600–mutated advanced melanoma who received an immunotherapy regimen of nivolumab/ipilimumab followed by targeted therapy with dabrafenib/trametinib experienced greater overall survival (72%) compared with patients receiving the converse sequence (52%). According to the study...
Numerous Regimens Proposed for Relapsed or Refractory Myeloma
Although patients with multiple myeloma can respond to initial treatment, once a patient has had three or four different types of therapy, and the disease is deemed relapsed or refractory, treatment becomes more complicated. This is related to both clinical characteristics, as patients may develop...
Study Explores Method to Selectively Grow Tumor-Targeting T Cells for Cancer Therapy
A preclinical study published by Arnaud et al in Nature Biotechnology has demonstrated the utility and efficacy of a highly efficient method to generate large numbers of immune cells specifically engineered to recognize neoantigens and destroy the tumors that express them. Developed by a team of...
Novel Drug Combination May Help Children With Acute Promyelocytic Leukemia Avoid Conventional Chemotherapy
A clinical trial recently published by Kutny et al in JAMA Oncology found that the combination of all-trans retinoic acid and arsenic trioxide was highly effective in children with standard- and high-risk acute promyelocytic leukemia (APL). Nearly all patients in the trial survived for 2 years...
Study Examines Immunotherapy Outcomes in Patients With Solid Tumors Who Are Ineligible for Clinical Trials
Patients with solid tumors who are ineligible for clinical trials receive immune checkpoint inhibitors at greater rates than patients who are eligible, despite no survival benefit, according to a recent study by researchers at the Perelman School of Medicine at the University of Pennsylvania. The...
NCI-Designated Cancer Center Compliance With CMS Price Transparency Rules
In a cross-sectional analysis reported in a research letter in JAMA Oncology, Chino et al found that a minority of National Cancer Institute (NCI)-designated cancer centers (NCI-CCs) were fully compliant with Centers for Medicare & Medicaid Services (CMS) price transparency rules. Study ...
Expert Point of View: Sophia C. Kamran, MD
Sophia C. Kamran, MD, a radiation oncologist at Massachusetts General Hospital and Assistant Professor of Radiation Oncology at Harvard Medical School, who was not involved in the RTOG 0815 study, commented: “The results of RTOG 0815 demonstrate that in the setting of contemporary dose-escalated...
International Conference Updates Guidelines for Advanced Breast Cancer
Patients with two out of the three most common types of advanced breast cancer now have an average survival time of at least 5 years, according to a panel of experts at the Advanced Breast Cancer Sixth International Consensus Conference (ABC6), which was held virtually this year. The Advanced...
Second Surprise Billing Rule Covers Dispute Resolution Processes, Good Faith Estimates for the Uninsured
On September 30, 2021, the U.S. Department of Health and Human Services (HHS), the Department of Labor, and the Department of the Treasury (“the Departments”), along with the Office of Personnel Management, released an interim final rule with comment period, entitled “Requirements Related to...
Living in Survival Mode
About 10 years ago, on a flight to Detroit, while returning from the San Antonio Breast Cancer Symposium, I had a conversation with Lori Pierce, MD, FASTRO, FASCO, radiation oncologist at the University of Michigan, who went on to become ASCO President for the 2020–2021 term. I recall inviting her...
Expert Point of View: Monica Arnedos, MD, PhD
The invited discussant of BrighTNess,1 Monica Arnedos, MD, PhD, Head of the Breast Cancer Research Program at the Institut Bergonié in Bordeaux, France, said the findings add to growing support for using carboplatin in triple-negative breast cancer, but their clinical application could be...
Expert Point of View: Michaela A. Dinan, PhD
Invited discussant of the study on medication nonadherence, Michaela A. Dinan, PhD, Co-Leader of Cancer Prevention and Control at Yale Cancer Center and Associate Professor of Chronic Disease Epidemiology at the Yale School of Public Health, in Connecticut, noted that the CAHPS survey data provide...
Medication Nonadherence Among Cancer Survivors: Are Indirect Health-Care Costs to Blame?
Approximately 1 in 10 long-term survivors of cancer fails to take medications as prescribed due to financial hardship, according to research presented at the 2021 ASCO Quality Care Symposium.1 However, indirect health-care costs—not drug copays—may be responsible, the study investigators ...
The Worst Part of Having Cancer Was the Guilt
When I was diagnosed with small cell lung cancer in 1992, at age 38, I remember thinking, “I wish I had breast cancer.” Breast cancer elicits such sympathy from people. A diagnosis of small cell lung cancer mainly gets you stern looks of disapproval and disappointment. There is so much stigma...
AML Pioneer and ‘Gentle Soul,’ Elihu H. Estey, MD, Dies at 75
“A lot of times, younger bright physicians are afraid to say what they really think, out of fear of challenging the dogma. One of the things I do when mentoring is to ask why we are doing a particular therapy or intervention. I tell my mentees not to let the data interfere with your knowledge,”...
Early Experiences in the United States Helped Shape an International Oncology Career for Aleix Prat, MD, PhD
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Aleix Prat, MD, PhD, Head of the Medical Oncology Department, Hospital Clinic of Barcelona. Dr. Prat, a breast cancer researcher, is currently working to identify strategies to tailor treatment for...
Study Examines Breakthrough COVID-19 Infection in Vaccinated Patients With Hematologic Cancers
People with blood cancers are at a higher risk than healthy individuals for severe infection with COVID-19; furthermore, research suggests that they do not always achieve optimal protection from vaccination. A new study published by Pagano et al in the journal Blood—the first to report on...
Expert Point of View: Benjamin Besse, MD
Invited discussant Benjamin Besse, MD, of Gustave Roussy Cancer Center, Villejuif, France, was generally positive about the findings of Impower010 but said that longer-term follow-up of overall survival will be very important. “IMpower010 is the first adjuvant study establishing an immune...
IMpower010: Adjuvant Atezolizumab Improves Disease-Free Survival and NSCLC Relapse in Patients Whose Tumors Express PD-L1
Adjuvant immunotherapy with atezolizumab after standard chemotherapy improved disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of patients with stage II to IIIA non–small cell lung cancer (NSCLC), according to an...
Fear of Side Effects and Lack of Awareness: Barriers to Greater Use of Risk-Reducing Medications for Breast Cancer
A “big problem, maybe the major one,” with risk-reducing medications for breast cancer is low uptake among women at high risk of breast cancer,” Seema A. Khan, MD, told participants at the 2021 Annual Lynn Sage Breast Cancer Symposium.1 Dr. Khan is Professor of Surgery and the Bluhm Family...
Risk-Reducing Medications for Breast Cancer Are Becoming Safer and More Tolerable
Risk-reducing medications for breast cancer may be effective for many women, and recently reported and ongoing trials have led to improvements in their tolerability and safety, Seema A. Khan, MD, reported at the 2021 Annual Lynn Sage Breast Cancer Symposium (virtual).1 Dr. Khan is Professor of...
Optimizing Adjuvant Therapy for Women With Estrogen Receptor–Positive, Node-Positive Breast Cancer
“Nodal status remains the single most important prognostic marker in outcomes for women with estrogen receptor–positive, HER2-negative breast cancer. For that reason, it makes sense to think about optimizing adjuvant therapy, including endocrine treatments, chemotherapy, and targeted therapy,”...
Racial Disparities in Use of Prostate MRI After Detection of Elevated PSA Levels
In a study published by Abashidze et al in JAMA Network Open, the investigators found that Black men were at least 23.6% less likely than White men to undergo magnetic resonance imaging (MRI) following an elevated prostate-specific antigen (PSA) test result. They also found that Hispanic and Asian...
Ibrutinib Plus R-CHOP for Younger Patients With DLBCL
New evidence suggests that adding the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib to a standard chemotherapy regimen may improve survival among younger people with a specific form of diffuse large B-cell lymphoma (DLBCL). The findings, published by Wyndham Wilson, MD, PhD, in Cancer Cell,...
Expert Point of View: Michaela A. Dinan, PhD
The invited discussant of the study on out-of-pocket costs of cancer care, Michaela A. Dinan, PhD, Co-Leader of Cancer Prevention and Control at Yale Cancer Center and Associate Professor of Chronic Disease Epidemiology at the Yale School of Public Health, Connecticut, underscored the study’s key...
Out-of-Pocket Costs on the Rise for the Four Most Common Cancers, Study Finds
Rising cost-sharing requirements from private insurance have exacerbated the financial burden for patients with cancer, according to research presented at the 2021 ASCO Quality Care Symposium.1 Analysis of claims data on the four most prevalent cancers in the United States—female breast,...
Patients With Multiple Myeloma May Lack T-Cell Responses to COVID-19 Vaccination
Patients with multiple myeloma lacking an antibody response to COVID-19 vaccine may also fail to mount a T-cell response, according to research from the Icahn School of Medicine at Mount Sinai. Concerningly, this scenario was most common among patients actively treated with anti-CD38 and...
Study Examines Use of External-Beam Radiotherapy as a Bridging Therapy for Patients With HCC Awaiting Transplant
Patients with hepatocellular carcinoma (HCC) awaiting liver transplantation may benefit from noninvasive treatment with external-beam radiotherapy (EBRT) but are rarely given this therapy, according to a new analysis of U.S. national data. Findings were presented by Nima Nabavizadeh, MD, at the...
Annual Report to the Nation, Part 2: Focus on Patient Economic Burden Associated With Cancer Care
Part 2 of the latest Annual Report to the Nation on the Status of Cancer—provided by the American Cancer Society, National Cancer Institute, Centers for Disease Control and Prevention, and North American Association of Central Cancer Registries—has found that patients with cancer in the United...
Expert Point of View: Arjun Gupta, MBBS
Moderator of the session on oncology drug pricing, Arjun Gupta, MBBS, Assistant Professor of Medicine at the University of Minnesota Medical School, observed that generics alone may be insufficient to slow the astronomical rise of drug prices. “The general thinking has always been that generics...
Is Precision Oncology an Unsustainable Promise?
Despite the promise of precision oncology, the cost-effectiveness of targeted treatments remains open to debate. According to Aakash Desai, MD, MPH, there is an urgent need for drug-pricing reform, given the average expenditure of Medicare Part D. An analysis of the Medicare database presented...
Cardio-oncology
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Urbanization in Bangladesh: The Prevalence of Breast Cancer Brings Unique Challenges
The number of deaths related to breast cancer are increasing at an alarming pace worldwide. According to a World Health Organization (WHO) 2020 report, approximately 2,088,849 new cases and 627,000 deaths related to breast cancer occurred in 2018.1 More than 55% of these deaths occurred in low- to ...
An Atypical Road to a Career in Medicine and Leading a Cancer Center for Robert A. Winn, MD
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Robert A. Winn, MD, Director of VCU Massey Cancer Center, Richmond, Virginia. In 2020, he became the first Black physician to lead a National Cancer Institute–designated cancer center. Among other...
Financial Impact of Cardiovascular Disease and Cancer Care: Overlapping Toxicities
The leading causes of mortality in the United States are cardiovascular disease (23%) and cancer (21%), accounting for more than 40% of total deaths reported.1,2 The increasing rise in health-care expenditures over the past several decades has driven the need for metrics to further evaluate the...
Expert Point of View: Heather A. Wakelee, MD, FASCO, and Erika Hlavacek
Heather A. Wakelee, MD, FASCO, President of the International Association for the Study of Lung Cancer (IASLC), who moderated a press briefing where the results of the Atezo-Brain trial were presented, called the study “beautiful work designed specifically” for patients with non–small cell lung...
Aakash Desai, MPH, MD, on the Precision Oncology Promise: Can We Deliver?
Aakash Desai, MPH, MD, of the Mayo Clinic in Rochester, Minnesota, talks about the urgent need for drug pricing reform, given the average expenditure of Medicare part D, and the ultimate out-of-pocket costs for patients with cancer. The promise of precision oncology will fail, says Dr. Desai, if we ...
Expert Point of View: Johnie Rose, MD, PhD
Invited study discussant, Johnie Rose, MD, PhD, noted that screening is a complex problem that requires balancing the risks of avoidable metastatic prostate cancer with the serious complications associated with treatment. Dr. Rose is Assistant Professor at the Center for Community Health...
National Cancer Act and Lung Cancer Screening: An Example of Intended Impact
The National Cancer Act of 1971 established a national priority to address the widely shared dread of a cancer diagnosis. The goal of the National Cancer Act was to strengthen the National Cancer Institute (NCI) to more effectively carry out the national effort against cancer. After the Act was...
Do Patients Diagnosed With Cancer Living in Low-Income and Rural Areas Face an Increased Risk of Suicide?
Individuals diagnosed with cancer who live in low-income and rural areas may face an increased risk of suicide compared with patients living in high-income and urban areas, according to a study published by Suk et al in JAMA Network Open. The research focused on determining whether the risks and...
